Influence of Mechanical Ventilation on the Pharmacokinetics of Vancomycin Administered by Continuous Infusion in Critically Ill Patients

Pathophysiological changes involved in drug disposition in critically ill patients should be considered in order to optimize the dosing of vancomycin administered by continuous infusion, and certain strategies must be applied to reach therapeutic targets on the first day of treatment. The aim of thi...

Full description

Saved in:
Bibliographic Details
Published inAntimicrobial agents and chemotherapy Vol. 61; no. 12
Main Authors Medellín-Garibay, Susanna Edith, Romano-Moreno, Silvia, Tejedor-Prado, Pilar, Rubio-Álvaro, Noelia, Rueda-Naharro, Aida, Blasco-Navalpotro, Miguel Angel, García, Benito, Barcia, Emilia
Format Journal Article
LanguageEnglish
Published United States American Society for Microbiology 01.12.2017
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Pathophysiological changes involved in drug disposition in critically ill patients should be considered in order to optimize the dosing of vancomycin administered by continuous infusion, and certain strategies must be applied to reach therapeutic targets on the first day of treatment. The aim of this study was to develop a population pharmacokinetic model of vancomycin to determine clinical covariates, including mechanical ventilation, that influence the wide variability of this antimicrobial. Plasma vancomycin concentrations from 54 critically ill patients were analyzed simultaneously by a population pharmacokinetic approach. A nomogram for dosing recommendations was developed and was internally evaluated through stochastic simulations. The plasma vancomycin concentration-versus-time data were best described by a one-compartment open model with exponential interindividual variability associated with vancomycin clearance and the volume of distribution. Residual error followed a homoscedastic trend. Creatinine clearance and body weight significantly dropped the objective function value, showing their influence on vancomycin clearance and the volume of distribution, respectively. Characterization based on the presence of mechanical ventilation demonstrated a 20% decrease in vancomycin clearance. External validation ( = 18) was performed to evaluate the predictive ability of the model; median bias and precision values were 0.7 mg/liter (95% confidence interval [CI], -0.4, 1.7) and 5.9 mg/liter (95% CI, 5.4, 6.4), respectively. A population pharmacokinetic model was developed for the administration of vancomycin by continuous infusion to critically ill patients, demonstrating the influence of creatinine clearance and mechanical ventilation on vancomycin clearance, as well as the implications for targeting dosing rates to reach the therapeutic range (20 to 30 mg/liter).
AbstractList Pathophysiological changes involved in drug disposition in critically ill patients should be considered in order to optimize the dosing of vancomycin administered by continuous infusion, and certain strategies must be applied to reach therapeutic targets on the first day of treatment. The aim of this study was to develop a population pharmacokinetic model of vancomycin to determine clinical covariates, including mechanical ventilation, that influence the wide variability of this antimicrobial. Plasma vancomycin concentrations from 54 critically ill patients were analyzed simultaneously by a population pharmacokinetic approach. A nomogram for dosing recommendations was developed and was internally evaluated through stochastic simulations. The plasma vancomycin concentration-versus-time data were best described by a one-compartment open model with exponential interindividual variability associated with vancomycin clearance and the volume of distribution. Residual error followed a homoscedastic trend. Creatinine clearance and body weight significantly dropped the objective function value, showing their influence on vancomycin clearance and the volume of distribution, respectively. Characterization based on the presence of mechanical ventilation demonstrated a 20% decrease in vancomycin clearance. External validation ( n = 18) was performed to evaluate the predictive ability of the model; median bias and precision values were 0.7 mg/liter (95% confidence interval [CI], −0.4, 1.7) and 5.9 mg/liter (95% CI, 5.4, 6.4), respectively. A population pharmacokinetic model was developed for the administration of vancomycin by continuous infusion to critically ill patients, demonstrating the influence of creatinine clearance and mechanical ventilation on vancomycin clearance, as well as the implications for targeting dosing rates to reach the therapeutic range (20 to 30 mg/liter).
Pathophysiological changes involved in drug disposition in critically ill patients should be considered in order to optimize the dosing of vancomycin administered by continuous infusion, and certain strategies must be applied to reach therapeutic targets on the first day of treatment. The aim of this study was to develop a population pharmacokinetic model of vancomycin to determine clinical covariates, including mechanical ventilation, that influence the wide variability of this antimicrobial. Plasma vancomycin concentrations from 54 critically ill patients were analyzed simultaneously by a population pharmacokinetic approach. A nomogram for dosing recommendations was developed and was internally evaluated through stochastic simulations. The plasma vancomycin concentration-versus-time data were best described by a one-compartment open model with exponential interindividual variability associated with vancomycin clearance and the volume of distribution. Residual error followed a homoscedastic trend. Creatinine clearance and body weight significantly dropped the objective function value, showing their influence on vancomycin clearance and the volume of distribution, respectively. Characterization based on the presence of mechanical ventilation demonstrated a 20% decrease in vancomycin clearance. External validation ( = 18) was performed to evaluate the predictive ability of the model; median bias and precision values were 0.7 mg/liter (95% confidence interval [CI], -0.4, 1.7) and 5.9 mg/liter (95% CI, 5.4, 6.4), respectively. A population pharmacokinetic model was developed for the administration of vancomycin by continuous infusion to critically ill patients, demonstrating the influence of creatinine clearance and mechanical ventilation on vancomycin clearance, as well as the implications for targeting dosing rates to reach the therapeutic range (20 to 30 mg/liter).
Pathophysiological changes involved in drug disposition in critically ill patients should be considered in order to optimize the dosing of vancomycin administered by continuous infusion, and certain strategies must be applied to reach therapeutic targets on the first day of treatment. The aim of this study was to develop a population pharmacokinetic model of vancomycin to determine clinical covariates, including mechanical ventilation, that influence the wide variability of this antimicrobial. Plasma vancomycin concentrations from 54 critically ill patients were analyzed simultaneously by a population pharmacokinetic approach. A nomogram for dosing recommendations was developed and was internally evaluated through stochastic simulations. The plasma vancomycin concentration-versus-time data were best described by a one-compartment open model with exponential interindividual variability associated with vancomycin clearance and the volume of distribution. Residual error followed a homoscedastic trend. Creatinine clearance and body weight significantly dropped the objective function value, showing their influence on vancomycin clearance and the volume of distribution, respectively. Characterization based on the presence of mechanical ventilation demonstrated a 20% decrease in vancomycin clearance. External validation (n = 18) was performed to evaluate the predictive ability of the model; median bias and precision values were 0.7 mg/liter (95% confidence interval [CI], -0.4, 1.7) and 5.9 mg/liter (95% CI, 5.4, 6.4), respectively. A population pharmacokinetic model was developed for the administration of vancomycin by continuous infusion to critically ill patients, demonstrating the influence of creatinine clearance and mechanical ventilation on vancomycin clearance, as well as the implications for targeting dosing rates to reach the therapeutic range (20 to 30 mg/liter).
Pathophysiological changes involved in drug disposition in critically ill patients should be considered in order to optimize the dosing of vancomycin administered by continuous infusion, and certain strategies must be applied to reach therapeutic targets on the first day of treatment. The aim of this study was to develop a population pharmacokinetic model of vancomycin to determine clinical covariates, including mechanical ventilation, that influence the wide variability of this antimicrobial. Plasma vancomycin concentrations from 54 critically ill patients were analyzed simultaneously by a population pharmacokinetic approach. A nomogram for dosing recommendations was developed and was internally evaluated through stochastic simulations. The plasma vancomycin concentration-versus-time data were best described by a one-compartment open model with exponential interindividual variability associated with vancomycin clearance and the volume of distribution. Residual error followed a homoscedastic trend. Creatinine clearance and body weight significantly dropped the objective function value, showing their influence on vancomycin clearance and the volume of distribution, respectively. Characterization based on the presence of mechanical ventilation demonstrated a 20% decrease in vancomycin clearance. External validation (n = 18) was performed to evaluate the predictive ability of the model; median bias and precision values were 0.7 mg/liter (95% confidence interval [CI], −0.4, 1.7) and 5.9 mg/liter (95% CI, 5.4, 6.4), respectively. A population pharmacokinetic model was developed for the administration of vancomycin by continuous infusion to critically ill patients, demonstrating the influence of creatinine clearance and mechanical ventilation on vancomycin clearance, as well as the implications for targeting dosing rates to reach the therapeutic range (20 to 30 mg/liter).
ABSTRACT Pathophysiological changes involved in drug disposition in critically ill patients should be considered in order to optimize the dosing of vancomycin administered by continuous infusion, and certain strategies must be applied to reach therapeutic targets on the first day of treatment. The aim of this study was to develop a population pharmacokinetic model of vancomycin to determine clinical covariates, including mechanical ventilation, that influence the wide variability of this antimicrobial. Plasma vancomycin concentrations from 54 critically ill patients were analyzed simultaneously by a population pharmacokinetic approach. A nomogram for dosing recommendations was developed and was internally evaluated through stochastic simulations. The plasma vancomycin concentration-versus-time data were best described by a one-compartment open model with exponential interindividual variability associated with vancomycin clearance and the volume of distribution. Residual error followed a homoscedastic trend. Creatinine clearance and body weight significantly dropped the objective function value, showing their influence on vancomycin clearance and the volume of distribution, respectively. Characterization based on the presence of mechanical ventilation demonstrated a 20% decrease in vancomycin clearance. External validation ( n = 18) was performed to evaluate the predictive ability of the model; median bias and precision values were 0.7 mg/liter (95% confidence interval [CI], −0.4, 1.7) and 5.9 mg/liter (95% CI, 5.4, 6.4), respectively. A population pharmacokinetic model was developed for the administration of vancomycin by continuous infusion to critically ill patients, demonstrating the influence of creatinine clearance and mechanical ventilation on vancomycin clearance, as well as the implications for targeting dosing rates to reach the therapeutic range (20 to 30 mg/liter).
Author García, Benito
Tejedor-Prado, Pilar
Romano-Moreno, Silvia
Barcia, Emilia
Blasco-Navalpotro, Miguel Angel
Medellín-Garibay, Susanna Edith
Rubio-Álvaro, Noelia
Rueda-Naharro, Aida
Author_xml – sequence: 1
  givenname: Susanna Edith
  surname: Medellín-Garibay
  fullname: Medellín-Garibay, Susanna Edith
  organization: Departamento de Farmacia y Tecnología Farmacéutica, Facultad de Farmacia, Universidad Complutense de Madrid, Madrid, Spain
– sequence: 2
  givenname: Silvia
  surname: Romano-Moreno
  fullname: Romano-Moreno, Silvia
  email: srm@uaslp.mx
  organization: Departamento de Farmacia y Tecnología de Medicamentos, Facultad de Ciencias Químicas, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico srm@uaslp.mx
– sequence: 3
  givenname: Pilar
  surname: Tejedor-Prado
  fullname: Tejedor-Prado, Pilar
  organization: Hospital Universitario Severo Ochoa, Leganes, Spain
– sequence: 4
  givenname: Noelia
  surname: Rubio-Álvaro
  fullname: Rubio-Álvaro, Noelia
  organization: Hospital Universitario Severo Ochoa, Leganes, Spain
– sequence: 5
  givenname: Aida
  surname: Rueda-Naharro
  fullname: Rueda-Naharro, Aida
  organization: Hospital Universitario Severo Ochoa, Leganes, Spain
– sequence: 6
  givenname: Miguel Angel
  surname: Blasco-Navalpotro
  fullname: Blasco-Navalpotro, Miguel Angel
  organization: Hospital Universitario Severo Ochoa, Leganes, Spain
– sequence: 7
  givenname: Benito
  surname: García
  fullname: García, Benito
  organization: Hospital Universitario Severo Ochoa, Leganes, Spain
– sequence: 8
  givenname: Emilia
  surname: Barcia
  fullname: Barcia, Emilia
  organization: Departamento de Farmacia y Tecnología Farmacéutica, Facultad de Farmacia, Universidad Complutense de Madrid, Madrid, Spain
BackLink https://www.ncbi.nlm.nih.gov/pubmed/28893792$$D View this record in MEDLINE/PubMed
BookMark eNp1kU1rFTEUhoNU7G1151qytODUfMxkMhvhMvhxoWIX2m3IZE68qZmkJjPC_Qf-bDPeWnQhBELIk-fl5D1DJyEGQOg5JZeUMvl6u-0vCWV1V9H2EdpQ0slKNJ04QRtChKhqSepTdJbzLSnnpiNP0CmTsuNtxzbo5y5Yv0AwgKPFH8HsdXBGe3wDYXZezy4GXNa8B3y912nSJn5zAWZn8vriRgcTp4NxAW_HyQWXZ0gw4uGA-1gMYYlLxiVkyaupYH1y85rgD3jnPb4uESUqP0WPrfYZnt3v5-jLu7ef-w_V1af3u357VemayrkS7SB5U1ugIxPADdNCMjM2DQykq5mmTBO9Al2rCa1HK4SVrbWUM27awfJz9ObovVuGCUZTspP26i65SaeDitqpf2-C26uv8YdqWkK4qIvg5b0gxe8L5FlNLhvwXgcosyracckIp1QW9NURNSnmnMA-xFCi1vJUKU_9Lk_RtuAXR1znianbuKRQfuJ_7Iu_x3gQ_2mW_wKMd6ap
CitedBy_id crossref_primary_10_1080_17512433_2023_2295009
crossref_primary_10_1097_FTD_0000000000000801
crossref_primary_10_3389_fmicb_2021_649757
crossref_primary_10_1007_s40262_023_01213_x
crossref_primary_10_1016_j_cmi_2020_07_005
crossref_primary_10_1007_s40262_020_00866_2
crossref_primary_10_1515_med_2018_0068
crossref_primary_10_1002_jcph_2375
crossref_primary_10_1093_jac_dkz158
crossref_primary_10_1136_ejhpharm_2020_002637
crossref_primary_10_3390_pharmaceutics15051411
crossref_primary_10_1007_s00228_023_03511_6
crossref_primary_10_1016_j_ijantimicag_2022_106579
crossref_primary_10_1128_AAC_01209_18
crossref_primary_10_1016_j_biopha_2022_113777
crossref_primary_10_1016_j_ijantimicag_2019_09_018
crossref_primary_10_1128_AAC_02543_18
crossref_primary_10_1016_j_cmi_2019_02_029
crossref_primary_10_3389_fphar_2022_1005791
crossref_primary_10_1111_jphp_13071
crossref_primary_10_3390_pharmaceutics12070638
Cites_doi 10.1007/BF01726369
10.1128/AAC.03147-14
10.1007/s40262-016-0475-3
10.1016/j.ijantimicag.2010.09.004
10.1093/cid/cir034
10.1016/j.jcrc.2012.02.003
10.1159/000180580
10.1038/psp.2013.24
10.1128/AAC.00330-16
10.1111/jcpt.12270
10.1016/S0169-2607(98)00067-4
10.1592/phco.29.11.1275
10.1086/491712
10.1128/AAC.01149-08
10.1128/AAC.01472-10
10.1007/BF01060893
10.1128/AAC.00168-11
10.1111/jcpt.12088
10.1093/jac/dkt402
10.1111/j.1365-2125.2010.03679.x
10.1111/j.1365-2710.2006.00762.x
10.7399/fh.2017.41.2.10591
10.1128/AAC.45.9.2460-2467.2001
10.1016/j.jcrc.2013.12.007
10.1097/CCM.0b013e3181961bff
10.1016/j.cmpb.2005.04.005
10.2165/00003088-200544100-00002
10.1097/FTD.0000000000000295
10.1128/AAC.37.2.281
10.1128/JCM.01388-06
10.1111/j.1365-2710.2004.00572.x
10.1038/psp.2013.14
10.2165/11318140-000000000-00000
10.1378/chest.11-1396
10.1186/2110-5820-1-26
10.1186/s13054-014-0654-2
10.1128/AAC.01708-10
10.1007/s40262-016-0435-y
10.1093/jac/dks328
10.1177/106002808902300408
10.1093/jac/dkv372
10.1128/AAC.01485-12
10.1128/AAC.01568-12
10.1002/9780470087978.ch8
ContentType Journal Article
Copyright Copyright © 2017 American Society for Microbiology.
Copyright © 2017 American Society for Microbiology. 2017 American Society for Microbiology
Copyright_xml – notice: Copyright © 2017 American Society for Microbiology.
– notice: Copyright © 2017 American Society for Microbiology. 2017 American Society for Microbiology
DBID NPM
AAYXX
CITATION
7X8
5PM
DOI 10.1128/AAC.01249-17
DatabaseName PubMed
CrossRef
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle PubMed
CrossRef
MEDLINE - Academic
DatabaseTitleList
PubMed
MEDLINE - Academic

CrossRef
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Biology
Pharmacy, Therapeutics, & Pharmacology
DocumentTitleAlternate Vancomycin Pharmacokinetics in Critically Ill Patients, Medellín-Garibay et al
Vancomycin Pharmacokinetics in Critically Ill Patients
EISSN 1098-6596
ExternalDocumentID 10_1128_AAC_01249_17
01249-17
28893792
Genre Journal Article
GrantInformation_xml – fundername: Consejo Nacional de Ciencia y Tecnología (CONACYT)
  grantid: 237235
  funderid: https://doi.org/10.13039/501100003141
– fundername: Consejo Nacional de Ciencia y Tecnología (CONACYT)
  grantid: 237235
GroupedDBID ---
.55
.GJ
0R~
23M
2WC
39C
3O-
4.4
53G
5GY
5RE
5VS
6J9
ACGFO
ADBBV
AENEX
AGNAY
AGVNZ
AI.
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BTFSW
C1A
CS3
DIK
E3Z
EBS
EJD
F5P
FRP
GX1
H13
HH5
HYE
HZ~
H~9
J5H
K-O
KQ8
L7B
LSO
MVM
NEJ
NPM
O9-
OK1
P2P
RHF
RHI
RNS
RPM
RSF
TR2
UHB
VH1
W2D
W8F
WH7
WHG
WOQ
X7M
X7N
XOL
Y6R
ZGI
ZXP
~A~
-
0R
55
AAPBV
ABFLS
ADACO
BXI
HZ
ZA5
AAYXX
CITATION
7X8
5PM
ID FETCH-LOGICAL-a418t-67b8354fe1d26e3c2a682cd55eb0942a12a0a354f97a014df66f87ff1323c7bf3
IEDL.DBID RPM
ISSN 0066-4804
IngestDate Tue Sep 17 21:22:04 EDT 2024
Sat Oct 05 04:38:01 EDT 2024
Thu Sep 12 17:21:10 EDT 2024
Tue Dec 28 13:59:23 EST 2021
Wed Oct 16 01:00:09 EDT 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 12
Keywords vancomycin
dosing recommendations
intensive care
mechanical ventilation
stochastic simulations
population pharmacokinetics
Language English
License Copyright © 2017 American Society for Microbiology.
All Rights Reserved . https://doi.org/10.1128/ASMCopyrightv2
All Rights Reserved.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-a418t-67b8354fe1d26e3c2a682cd55eb0942a12a0a354f97a014df66f87ff1323c7bf3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Citation Medellín-Garibay SE, Romano-Moreno S, Tejedor-Prado P, Rubio-Álvaro N, Rueda-Naharro A, Blasco-Navalpotro MA, García B, Barcia E. 2017. Influence of mechanical ventilation on the pharmacokinetics of vancomycin administered by continuous infusion in critically ill patients. Antimicrob Agents Chemother 61:e01249-17. https://doi.org/10.1128/AAC.01249-17.
OpenAccessLink https://aac.asm.org/content/aac/61/12/e01249-17.full.pdf
PMID 28893792
PQID 1938203118
PQPubID 23479
PageCount 10
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_5700364
proquest_miscellaneous_1938203118
crossref_primary_10_1128_AAC_01249_17
asm2_journals_10_1128_AAC_01249_17
pubmed_primary_28893792
PublicationCentury 2000
PublicationDate 2017-12-01
PublicationDateYYYYMMDD 2017-12-01
PublicationDate_xml – month: 12
  year: 2017
  text: 2017-12-01
  day: 01
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: 1752 N St., N.W., Washington, DC
PublicationTitle Antimicrobial agents and chemotherapy
PublicationTitleAbbrev Antimicrob Agents Chemother
PublicationTitleAlternate Antimicrob Agents Chemother
PublicationYear 2017
Publisher American Society for Microbiology
Publisher_xml – name: American Society for Microbiology
References Lindbom, L, Pihlgren, P, Jonsson, EN (B40) 2005; 79
Contreiras, C, Legal, M, Lau, TT, Thalakada, R, Shalansky, S, Ensom, MH (B11) 2014; 67
Saugel, B, Gramm, C, Wagner, JY, Messer, M, Lahmer, T, Meidert, AS, Schmid, RM, Huber, W (B6) 2014; 29
Pea, F, Viale, P, Furlanut, M (B21) 2005; 44
Revilla, N, Martin-Suarez, A, Perez, MP, Gonzalez, FM, del Mar Fernandez de Gatta, M (B24) 2010; 70
Baptista, JP, Roberts, JA, Sousa, E, Freitas, R, Deveza, N, Pimentel, J (B13) 2014; 18
Rybak, MJ, Lomaestro, BM, Rotschafer, JC, Moellering, RC, Craig, WA, Billeter, M, Dalovisio, JR, Levine, DP (B3) 2009; 29
Vuagnat, A, Stern, R, Lotthe, A, Schuhmacher, H, Duong, M, Hoffmeyer, P, Bernard, L (B16) 2004; 29
Jonsson, EN, Karlsson, MO (B41) 1999; 58
van Hal, SJ, Paterson, DL, Lodise, TP (B8) 2013; 57
Cockcroft, DW, Gault, MH (B39) 1976; 16
Llopis-Salvia, P, Jiménez-Torres, NV (B25) 2006; 31
Wang, G, Hindler, JF, Ward, KW, Bruckner, DA (B36) 2006; 44
Zelenitsky, S, Alkurdi, N, Weber, Z, Ariano, R, Zhanel, G (B35) 2011; 55
Jeurissen, A, Sluyts, I, Rutsaert, R (B29) 2011; 37
Rybak, MJ (B4) 2006; 42
van Maarseveen, EM, Gipmans, S, Vasbinder, E, Petjak, M, van Zanten, AR (B23) 2016; 38
Perkins, MW, Dasta, JF, DeHaven, B (B31) 1989; 23
Liu, C, Bayer, A, Cosgrove, SE, Daum, RS, Fridkin, SK, Gorwitz, RJ, Kaplan, SL, Karchmer, AW, Levine, DP, Murray, BE, Rybak, MJ, Talan, DA, Chambers, HF (B1) 2011; 52
Carballo, N, De Antonio-Cusco, M, Echeverria-Esnal, D, Luque, S, Salas, E, Grau, S (B2) 2017; 41
Minkute, R, Briedis, V, Steponaviciute, R, Vitkauskiene, A, Maciulaitis, R (B34) 2013; 38
Waineo, MF, Kuhn, TC, Brown, DL (B17) 2015; 40
Verrall, AJ, Llorin, R, Tam, VH, Lye, DC, Sulaiman, Z, Zhong, L, Archuleta, S, Fisher, DA (B15) 2012; 67
Roberts, JA, Taccone, FS, Udy, AA, Vincent, JL, Jacobs, F, Lipman, J (B19) 2011; 55
Radke, C, Horn, D, Lanckohr, C, Ellger, B, Meyer, M, Eissing, T, Hempel, G (B26) 2017
Lamer, C, de Beco, V, Soler, P, Calvat, S, Fagon, JY, Dombret, MC, Farinotti, R, Chastre, J, Gibert, C (B32) 1993; 37
Williams, PJ, Kim, YH, Ette, EI, Ette, EI, Williams, PJ (B45) 2007
Smith, BS, Yogaratnam, D, Levasseur-Franklin, KE, Forni, A, Fong, J (B28) 2012; 141
Prybylski, JP (B7) 2017; 56
Sheiner, LB, Beal, SL (B44) 1981; 9
Wysocki, M, Delatour, F, Faurisson, F, Rauss, A, Pean, Y, Misset, B, Thomas, F, Timsit, JF, Similowski, T, Mentec, H, Mier, L, Dreyfuss, D (B12) 2001; 45
Mould, DR, Upton, RN (B43) 2013; 2
Cristallini, S, Hites, M, Kabtouri, H, Roberts, JA, Beumier, M, Cotton, F, Lipman, J, Jacobs, F, Vincent, JL, Creteur, J, Taccone, FS (B14) 2016; 60
Alvarez, R, Lopez Cortes, LE, Molina, J, Cisneros, JM, Pachon, J (B9) 2016; 60
Keizer, RJ, Karlsson, MO, Hooker, A (B42) 2013; 2
Norton, K, Ingram, PR, Heath, CH, Manning, L (B38) 2014; 69
Holmes, NE, Turnidge, JD, Munckhof, WJ, Robinson, JO, Korman, TM, O'Sullivan, MV, Anderson, TL, Roberts, SA, Warren, SJ, Gao, W, Howden, BP, Johnson, PD (B5) 2013; 57
Roberts, JA, Lipman, J (B18) 2009; 37
Spapen, HD, Janssen van Doorn, K, Diltoer, M, Verbrugghe, W, Jacobs, R, Dobbeleir, N, Honore, PM, Jorens, PG (B37) 2011; 1
Georges, H, Leroy, O, Alfandari, S, Guery, B, Roussel-Delvallez, M, Dhennain, C, Beaucaire, G (B33) 1997; 16
Udy, AA, Roberts, JA, Boots, RJ, Paterson, DL, Lipman, J (B20) 2010; 49
Saugel, B, Nowack, MC, Hapfelmeier, A, Umgelter, A, Schultheiss, C, Thies, P, Phillip, V, Eyer, F, Schmid, RM, Huber, W (B30) 2013; 28
Bosso, JA, Nappi, J, Rudisill, C, Wellein, M, Bookstaver, PB, Swindler, J, Mauldin, PD (B10) 2011; 55
Pea, F, Furlanut, M, Negri, C, Pavan, F, Crapis, M, Cristini, F, Viale, P (B22) 2009; 53
Medellín-Garibay, SE, Ortiz-Martin, B, Rueda-Naharro, A, Garcia, B, Romano-Moreno, S, Barcia, E (B27) 2016; 71
e_1_3_2_26_2
e_1_3_2_27_2
e_1_3_2_28_2
e_1_3_2_29_2
e_1_3_2_41_2
e_1_3_2_40_2
e_1_3_2_20_2
e_1_3_2_43_2
e_1_3_2_21_2
e_1_3_2_42_2
Contreiras C (e_1_3_2_12_2) 2014; 67
e_1_3_2_22_2
e_1_3_2_45_2
e_1_3_2_23_2
e_1_3_2_44_2
e_1_3_2_24_2
e_1_3_2_25_2
e_1_3_2_46_2
e_1_3_2_9_2
e_1_3_2_15_2
e_1_3_2_38_2
e_1_3_2_8_2
e_1_3_2_16_2
e_1_3_2_37_2
e_1_3_2_7_2
e_1_3_2_17_2
e_1_3_2_6_2
e_1_3_2_18_2
e_1_3_2_39_2
e_1_3_2_19_2
e_1_3_2_30_2
e_1_3_2_32_2
e_1_3_2_10_2
e_1_3_2_31_2
e_1_3_2_5_2
e_1_3_2_11_2
e_1_3_2_34_2
e_1_3_2_4_2
e_1_3_2_33_2
e_1_3_2_3_2
e_1_3_2_13_2
e_1_3_2_36_2
e_1_3_2_2_2
e_1_3_2_14_2
e_1_3_2_35_2
References_xml – volume: 16
  start-page: 385
  year: 1997
  end-page: 388
  ident: B33
  article-title: Pulmonary disposition of vancomycin in critically ill patients
  publication-title: Eur J Clin Microbiol Infect Dis
  doi: 10.1007/BF01726369
  contributor:
    fullname: Beaucaire, G
– volume: 60
  start-page: 2601
  year: 2016
  end-page: 2609
  ident: B9
  article-title: Optimizing the clinical use of vancomycin
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.03147-14
  contributor:
    fullname: Pachon, J
– year: 2017
  ident: B26
  article-title: Development of a physiologically based pharmacokinetic modelling approach to predict the pharmacokinetics of vancomycin in critically ill septic patients
  publication-title: Clin Pharmacokinet
  doi: 10.1007/s40262-016-0475-3
  contributor:
    fullname: Hempel, G
– volume: 37
  start-page: 75
  year: 2011
  end-page: 77
  ident: B29
  article-title: A higher dose of vancomycin in continuous infusion is needed in critically ill patients
  publication-title: Int J Antimicrob Agents
  doi: 10.1016/j.ijantimicag.2010.09.004
  contributor:
    fullname: Rutsaert, R
– volume: 52
  start-page: 285
  year: 2011
  end-page: 292
  ident: B1
  article-title: Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary
  publication-title: Clin Infect Dis
  doi: 10.1093/cid/cir034
  contributor:
    fullname: Chambers, HF
– volume: 28
  start-page: 9
  year: 2013
  end-page: 13
  ident: B30
  article-title: Continuous intravenous administration of vancomycin in medical intensive care unit patients
  publication-title: J Crit Care
  doi: 10.1016/j.jcrc.2012.02.003
  contributor:
    fullname: Huber, W
– volume: 16
  start-page: 31
  year: 1976
  end-page: 41
  ident: B39
  article-title: Prediction of creatinine clearance from serum creatinine
  publication-title: Nephron
  doi: 10.1159/000180580
  contributor:
    fullname: Gault, MH
– volume: 2
  start-page: e50
  year: 2013
  ident: B42
  article-title: Modeling and simulation workbench for NONMEM: tutorial on Pirana, PsN, and Xpose
  publication-title: CPT Pharmacometrics Syst Pharmacol
  doi: 10.1038/psp.2013.24
  contributor:
    fullname: Hooker, A
– volume: 60
  start-page: 4750
  year: 2016
  end-page: 4756
  ident: B14
  article-title: New regimen for continuous infusion of vancomycin in critically ill patients
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.00330-16
  contributor:
    fullname: Taccone, FS
– volume: 40
  start-page: 259
  year: 2015
  end-page: 265
  ident: B17
  article-title: The pharmacokinetic/pharmacodynamic rationale for administering vancomycin via continuous infusion
  publication-title: J Clin Pharm Ther
  doi: 10.1111/jcpt.12270
  contributor:
    fullname: Brown, DL
– volume: 58
  start-page: 51
  year: 1999
  end-page: 64
  ident: B41
  article-title: Xpose—an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM
  publication-title: Comput Methods Programs Biomed
  doi: 10.1016/S0169-2607(98)00067-4
  contributor:
    fullname: Karlsson, MO
– volume: 29
  start-page: 1275
  year: 2009
  end-page: 1279
  ident: B3
  article-title: Therapeutic monitoring of vancomycin in adults: summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists
  publication-title: Pharmacotherapy
  doi: 10.1592/phco.29.11.1275
  contributor:
    fullname: Levine, DP
– volume: 42
  start-page: S35
  year: 2006
  end-page: S39
  ident: B4
  article-title: The pharmacokinetic and pharmacodynamic properties of vancomycin
  publication-title: Clin Infect Dis
  doi: 10.1086/491712
  contributor:
    fullname: Rybak, MJ
– volume: 53
  start-page: 1863
  year: 2009
  end-page: 1867
  ident: B22
  article-title: Prospectively validated dosing nomograms for maximizing the pharmacodynamics of vancomycin administered by continuous infusion in critically ill patients
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.01149-08
  contributor:
    fullname: Viale, P
– volume: 55
  start-page: 3627
  year: 2011
  end-page: 3630
  ident: B35
  article-title: Preferential emergence of reduced vancomycin susceptibility in health care-associated methicillin-resistant Staphylococcus aureus isolates during continuous-infusion vancomycin therapy in an in vitro dynamic model
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.01472-10
  contributor:
    fullname: Zhanel, G
– volume: 9
  start-page: 503
  year: 1981
  end-page: 512
  ident: B44
  article-title: Some suggestions for measuring predictive performance
  publication-title: J Pharmacokinet Biopharm
  doi: 10.1007/BF01060893
  contributor:
    fullname: Beal, SL
– volume: 67
  start-page: 126
  year: 2014
  end-page: 132
  ident: B11
  article-title: Identification of risk factors for nephrotoxicity in patients receiving extended-duration, high-trough vancomycin therapy
  publication-title: Can J Hosp Pharm
  contributor:
    fullname: Ensom, MH
– start-page: 223
  year: 2007
  end-page: 245
  ident: B45
  article-title: The epistemology of pharmacometrics
  publication-title: Pharmacometrics: the science of quantitative pharmacology ;John Wiley & Sons ;Hoboken, NJ
  contributor:
    fullname: Williams, PJ
– volume: 55
  start-page: 5475
  year: 2011
  end-page: 5479
  ident: B10
  article-title: Relationship between vancomycin trough concentrations and nephrotoxicity: a prospective multicenter trial
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.00168-11
  contributor:
    fullname: Mauldin, PD
– volume: 38
  start-page: 462
  year: 2013
  end-page: 467
  ident: B34
  article-title: Augmented renal clearance—an evolving risk factor to consider during the treatment with vancomycin
  publication-title: J Clin Pharm Ther
  doi: 10.1111/jcpt.12088
  contributor:
    fullname: Maciulaitis, R
– volume: 69
  start-page: 805
  year: 2014
  end-page: 808
  ident: B38
  article-title: Risk factors for nephrotoxicity in patients receiving outpatient continuous infusions of vancomycin in an Australian tertiary hospital
  publication-title: J Antimicrob Chemother
  doi: 10.1093/jac/dkt402
  contributor:
    fullname: Manning, L
– volume: 70
  start-page: 201
  year: 2010
  end-page: 212
  ident: B24
  article-title: Vancomycin dosing assessment in intensive care unit patients based on a population pharmacokinetic/pharmacodynamic simulation
  publication-title: Br J Clin Pharmacol
  doi: 10.1111/j.1365-2125.2010.03679.x
  contributor:
    fullname: del Mar Fernandez de Gatta, M
– volume: 31
  start-page: 447
  year: 2006
  end-page: 454
  ident: B25
  article-title: Population pharmacokinetic parameters of vancomycin in critically ill patients
  publication-title: J Clin Pharm Ther
  doi: 10.1111/j.1365-2710.2006.00762.x
  contributor:
    fullname: Jiménez-Torres, NV
– volume: 41
  start-page: 187
  year: 2017
  end-page: 203
  ident: B2
  article-title: Community-acquired pneumonia caused by methicillin-resistant Staphylococcus aureus in critically-ill patients: systematic review
  publication-title: Farm Hosp
  doi: 10.7399/fh.2017.41.2.10591
  contributor:
    fullname: Grau, S
– volume: 45
  start-page: 2460
  year: 2001
  end-page: 2467
  ident: B12
  article-title: Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: prospective multicenter randomized study
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.45.9.2460-2467.2001
  contributor:
    fullname: Dreyfuss, D
– volume: 29
  start-page: 351
  year: 2014
  end-page: 355
  ident: B6
  article-title: Evaluation of a dosing regimen for continuous vancomycin infusion in critically ill patients: an observational study in intensive care unit patients
  publication-title: J Crit Care
  doi: 10.1016/j.jcrc.2013.12.007
  contributor:
    fullname: Huber, W
– volume: 37
  start-page: 840
  year: 2009
  end-page: 851
  ident: B18
  article-title: Pharmacokinetic issues for antibiotics in the critically ill patient
  publication-title: Crit Care Med
  doi: 10.1097/CCM.0b013e3181961bff
  contributor:
    fullname: Lipman, J
– volume: 79
  start-page: 241
  year: 2005
  end-page: 257
  ident: B40
  article-title: PsN-Toolkit—a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM
  publication-title: Comput Methods Programs Biomed
  doi: 10.1016/j.cmpb.2005.04.005
  contributor:
    fullname: Jonsson, EN
– volume: 44
  start-page: 1009
  year: 2005
  end-page: 1034
  ident: B21
  article-title: Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability
  publication-title: Clin Pharmacokinet
  doi: 10.2165/00003088-200544100-00002
  contributor:
    fullname: Furlanut, M
– volume: 38
  start-page: 398
  year: 2016
  end-page: 401
  ident: B23
  article-title: Switching from intermittent to continuous infusion of vancomycin in critically ill patients: toward a more robust exposure
  publication-title: Ther Drug Monit
  doi: 10.1097/FTD.0000000000000295
  contributor:
    fullname: van Zanten, AR
– volume: 37
  start-page: 281
  year: 1993
  end-page: 286
  ident: B32
  article-title: Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.37.2.281
  contributor:
    fullname: Gibert, C
– volume: 44
  start-page: 3883
  year: 2006
  end-page: 3886
  ident: B36
  article-title: Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period
  publication-title: J Clin Microbiol
  doi: 10.1128/JCM.01388-06
  contributor:
    fullname: Bruckner, DA
– volume: 29
  start-page: 351
  year: 2004
  end-page: 357
  ident: B16
  article-title: High dose vancomycin for osteomyelitis: continuous vs. intermittent infusion
  publication-title: J Clin Pharm Ther
  doi: 10.1111/j.1365-2710.2004.00572.x
  contributor:
    fullname: Bernard, L
– volume: 2
  start-page: e38
  year: 2013
  ident: B43
  article-title: Basic concepts in population modeling, simulation, and model-based drug development—part 2: introduction to pharmacokinetic modeling methods
  publication-title: CPT Pharmacometrics Syst Pharmacol
  doi: 10.1038/psp.2013.14
  contributor:
    fullname: Upton, RN
– volume: 49
  start-page: 1
  year: 2010
  end-page: 16
  ident: B20
  article-title: Augmented renal clearance: implications for antibacterial dosing in the critically ill
  publication-title: Clin Pharmacokinet
  doi: 10.2165/11318140-000000000-00000
  contributor:
    fullname: Lipman, J
– volume: 141
  start-page: 1327
  year: 2012
  end-page: 1336
  ident: B28
  article-title: Introduction to drug pharmacokinetics in the critically ill patient
  publication-title: Chest
  doi: 10.1378/chest.11-1396
  contributor:
    fullname: Fong, J
– volume: 1
  start-page: 26
  year: 2011
  ident: B37
  article-title: Retrospective evaluation of possible renal toxicity associated with continuous infusion of vancomycin in critically ill patients
  publication-title: Ann Intensive Care
  doi: 10.1186/2110-5820-1-26
  contributor:
    fullname: Jorens, PG
– volume: 18
  start-page: 654
  year: 2014
  ident: B13
  article-title: Decreasing the time to achieve therapeutic vancomycin concentrations in critically ill patients: developing and testing of a dosing nomogram
  publication-title: Crit Care
  doi: 10.1186/s13054-014-0654-2
  contributor:
    fullname: Pimentel, J
– volume: 55
  start-page: 2704
  year: 2011
  end-page: 2709
  ident: B19
  article-title: Vancomycin dosing in critically ill patients: robust methods for improved continuous-infusion regimens
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.01708-10
  contributor:
    fullname: Lipman, J
– volume: 56
  start-page: 263
  year: 2017
  end-page: 272
  ident: B7
  article-title: A strategy for dosing vancomycin to therapeutic targets using only trough concentrations
  publication-title: Clin Pharmacokinet
  doi: 10.1007/s40262-016-0435-y
  contributor:
    fullname: Prybylski, JP
– volume: 67
  start-page: 2970
  year: 2012
  end-page: 2973
  ident: B15
  article-title: Efficacy of continuous infusion of vancomycin for the outpatient treatment of methicillin-resistant Staphylococcus aureus infections
  publication-title: J Antimicrob Chemother
  doi: 10.1093/jac/dks328
  contributor:
    fullname: Fisher, DA
– volume: 23
  start-page: 316
  year: 1989
  end-page: 323
  ident: B31
  article-title: Physiologic implications of mechanical ventilation on pharmacokinetics
  publication-title: DICP
  doi: 10.1177/106002808902300408
  contributor:
    fullname: DeHaven, B
– volume: 71
  start-page: 471
  year: 2016
  end-page: 479
  ident: B27
  article-title: Pharmacokinetics of vancomycin and dosing recommendations for trauma patients
  publication-title: J Antimicrob Chemother
  doi: 10.1093/jac/dkv372
  contributor:
    fullname: Barcia, E
– volume: 57
  start-page: 1654
  year: 2013
  end-page: 1663
  ident: B5
  article-title: Vancomycin AUC/MIC ratio and 30-day mortality in patients with Staphylococcus aureus bacteremia
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.01485-12
  contributor:
    fullname: Johnson, PD
– volume: 57
  start-page: 734
  year: 2013
  end-page: 744
  ident: B8
  article-title: Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.01568-12
  contributor:
    fullname: Lodise, TP
– ident: e_1_3_2_41_2
  doi: 10.1016/j.cmpb.2005.04.005
– ident: e_1_3_2_2_2
  doi: 10.1093/cid/cir034
– ident: e_1_3_2_38_2
  doi: 10.1186/2110-5820-1-26
– ident: e_1_3_2_4_2
  doi: 10.1592/phco.29.11.1275
– ident: e_1_3_2_43_2
  doi: 10.1038/psp.2013.24
– ident: e_1_3_2_44_2
  doi: 10.1038/psp.2013.14
– ident: e_1_3_2_6_2
  doi: 10.1128/AAC.01485-12
– ident: e_1_3_2_31_2
  doi: 10.1016/j.jcrc.2012.02.003
– ident: e_1_3_2_10_2
  doi: 10.1128/AAC.03147-14
– ident: e_1_3_2_26_2
  doi: 10.1111/j.1365-2710.2006.00762.x
– ident: e_1_3_2_25_2
  doi: 10.1111/j.1365-2125.2010.03679.x
– ident: e_1_3_2_39_2
  doi: 10.1093/jac/dkt402
– ident: e_1_3_2_29_2
  doi: 10.1378/chest.11-1396
– ident: e_1_3_2_11_2
  doi: 10.1128/AAC.00168-11
– ident: e_1_3_2_20_2
  doi: 10.1128/AAC.01708-10
– ident: e_1_3_2_30_2
  doi: 10.1016/j.ijantimicag.2010.09.004
– ident: e_1_3_2_9_2
  doi: 10.1128/AAC.01568-12
– ident: e_1_3_2_45_2
  doi: 10.1007/BF01060893
– ident: e_1_3_2_5_2
  doi: 10.1086/491712
– ident: e_1_3_2_40_2
  doi: 10.1159/000180580
– volume: 67
  start-page: 126
  year: 2014
  ident: e_1_3_2_12_2
  article-title: Identification of risk factors for nephrotoxicity in patients receiving extended-duration, high-trough vancomycin therapy
  publication-title: Can J Hosp Pharm
  contributor:
    fullname: Contreiras C
– ident: e_1_3_2_24_2
  doi: 10.1097/FTD.0000000000000295
– ident: e_1_3_2_3_2
  doi: 10.7399/fh.2017.41.2.10591
– ident: e_1_3_2_14_2
  doi: 10.1186/s13054-014-0654-2
– ident: e_1_3_2_28_2
  doi: 10.1093/jac/dkv372
– ident: e_1_3_2_46_2
  doi: 10.1002/9780470087978.ch8
– ident: e_1_3_2_42_2
  doi: 10.1016/S0169-2607(98)00067-4
– ident: e_1_3_2_22_2
  doi: 10.2165/00003088-200544100-00002
– ident: e_1_3_2_23_2
  doi: 10.1128/AAC.01149-08
– ident: e_1_3_2_8_2
  doi: 10.1007/s40262-016-0435-y
– ident: e_1_3_2_21_2
  doi: 10.2165/11318140-000000000-00000
– ident: e_1_3_2_15_2
  doi: 10.1128/AAC.00330-16
– ident: e_1_3_2_33_2
  doi: 10.1128/AAC.37.2.281
– ident: e_1_3_2_34_2
  doi: 10.1007/BF01726369
– ident: e_1_3_2_7_2
  doi: 10.1016/j.jcrc.2013.12.007
– ident: e_1_3_2_37_2
  doi: 10.1128/JCM.01388-06
– ident: e_1_3_2_27_2
  doi: 10.1007/s40262-016-0475-3
– ident: e_1_3_2_13_2
  doi: 10.1128/AAC.45.9.2460-2467.2001
– ident: e_1_3_2_35_2
  doi: 10.1111/jcpt.12088
– ident: e_1_3_2_16_2
  doi: 10.1093/jac/dks328
– ident: e_1_3_2_18_2
  doi: 10.1111/jcpt.12270
– ident: e_1_3_2_32_2
  doi: 10.1177/106002808902300408
– ident: e_1_3_2_17_2
  doi: 10.1111/j.1365-2710.2004.00572.x
– ident: e_1_3_2_36_2
  doi: 10.1128/AAC.01472-10
– ident: e_1_3_2_19_2
  doi: 10.1097/CCM.0b013e3181961bff
SSID ssj0006590
Score 2.4202054
Snippet Pathophysiological changes involved in drug disposition in critically ill patients should be considered in order to optimize the dosing of vancomycin...
ABSTRACT Pathophysiological changes involved in drug disposition in critically ill patients should be considered in order to optimize the dosing of vancomycin...
SourceID pubmedcentral
proquest
crossref
asm2
pubmed
SourceType Open Access Repository
Aggregation Database
Index Database
SubjectTerms Anti-Bacterial Agents
Clinical Therapeutics
Creatinine
Critical Illness
Respiration, Artificial
Vancomycin
Title Influence of Mechanical Ventilation on the Pharmacokinetics of Vancomycin Administered by Continuous Infusion in Critically Ill Patients
URI https://www.ncbi.nlm.nih.gov/pubmed/28893792
https://journals.asm.org/doi/10.1128/AAC.01249-17
https://search.proquest.com/docview/1938203118
https://pubmed.ncbi.nlm.nih.gov/PMC5700364
Volume 61
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV07b9swED4kBlJ0KVr3EfcRMEWbKbItiqKo0TAaxClceEiCbAIlkYgRWw4qe9A_6M_unSQ6cYMuAbSJFAXdUffgd98BfJNcx5znlNcQgSfyyHra16FnFI9TEYthzqneefpLnl-Ji5vwZg9CVwtTg_azdN4vFst-Mb-tsZX3y2zgcGKD2XRMnOyBFIN92EcFdSF6-_uVYZNYQVvqCTUUDu3O1WA0GveH1G3Z86n5HldkrOkQtKPLJd-1TE_czX9Rk4_M0NlreNX6j2zUvOcb2DNFFw6ajpJVF15M27PyLpzMGlbq6pRdPhRZlafshM0e-Kqrt_Bn4hqVsJVlU0O1wCQ6dk1IogYrx_BCV3E78w6XoKfRjGtUnNWywlWZo-KlBqAsrRhxX82LzWpTMlxkQ5k5hsNcf4VFxSaLBZs13K7lO7g6-3E5PvfaBg2eFr5aezJKKW9kjZ9zaYKMa6l4loehSTFq5NrneqhpQBxpDMVyK6VVkbUYAQdZlNrgPXSKVWEOgdlcCkNcbFYHIkZ1kblSVvE05NYXmvfgK8koaXdYmdTBC1cJyjSpZZr4UQ--Owkm9w1Zx3_GHTvxJrib6IhEFwa_RYLuLLpEAUZdPfjQiHv7JKcuPYh2FGE7gJi6d--gAteM3a3Cfnz2zE_wkpM_UeNoPkNn_XtjvqA3tE6PMA6Y_Dyq98BfgMgKKQ
link.rule.ids 230,315,730,783,787,888,27938,27939,53808,53810
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwEB4tRTwuPAos5WkQ7GnTJo7jOMeqYtXCdtVDt9pb5Dwsqm3T1bY9hF_Az2Ymibt0EQeQcvNLTj7HM-PP3wB8klxHnGcU1xC-I7LQONrTgZMrHiUiEm7G6b7z-EwOz8XXi-DiAAJ7F6Yi7afJvFsslt1i_r3iVl4t057lifUm4wFpsvtS9O7AXVyvrrJOevMDlkEdWsHd1BHKFZbvzlWv3x90Xcq37HiUfo8r2q7pGLSl10u-vzf9YXDe5k3-thGdPIaZnULNP7nsbjdJN_1xS93xn-f4BB41pinr18VP4SAv2nCvTlZZtuH-uDmGb8PRpBa8Lo_Z9Ob-1vqYHbHJjRR2-Qx-jmwOFLYybJzTNWNCBZsRSamm4TF80ArdtbzEIag3ajFDTK6WJY7KrMov5RZlSclIVmtebFfbNcNBthT0Y1jNpm5YlGy0WLBJLRu7fg7nJ1-mg6HT5H5wtPDUxpFhQiEpk3sZl7mfci0VT7MgyBN0SLn2uHY1VYhCjV5eZqQ0KjQGnWs_DRPjv4BWsSryl8BMJkVOMm9G-yJCJMpMKaN4EnDjCc078JE-ftws3nVc-UVcxQiWuAJL7IUd-GyhEV_VOiB_qffB4ibGhUqnL7rI8V3EaCmjteWjQ9eBwxpHu54sDjsQ7iFsV4FEwPdLEDeVGHiDk1f_3fI9PBhOx6fx6ejs22t4yMlsqeg6b6C1ud7mb9Ho2iTvqiX2C_GOKyM
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFD6CIqa9cCmMlatBsKclaRzHcR6rQrUCnfKwTRMvkZPYolqbVqR5CL-An41PLt06xMukvOXYlqPPOefYn78D8JFTGVKa4b4G8yyWBdqSrvQtJWiYsJANM4r3nWen_OScfb30L2-U-qpJ-2kyt_PF0s7nP2tu5XqZOh1PzIlmY9Rk9zhz1pl27sMDH1WqukS9_Qlzv9leMR7VYmLIOs47Fc5oNLaHWHPZcrEEHxXosvEotCeLJd31T_8Enbe5kzec0eQx_Oim0XBQruxyk9jp71sKj3ea5xN41IaoZNSYPIV7Ku_Dw6ZoZdWHvVl7HN-Ho6gRvq6Oydn1Pa7imByR6FoSu3oGf6ZdLRSy0mSm8LoxooNcIFmpoeMR85hodNvyygyBvWGLC4PN1bIyo5JO7RdrjJKkIiivNc_LVVkQM0iJm3_EmHUlHBYVmS4WJGrkY4vncD75cjY-sdoaEJZkrthYPEhwa0orN6NceSmVXNA0832VmMSUSpfKoUSDMJAm28s051oEWpsk20uDRHsH0MtXuToEojPOFMq9aemx0CCSZ0JoQROfapdJOoAPCIC4XcRFXOdHVMQGMHENmNgNBvCpg0e8bvRA_mP3vsNObBYsnsLIXJlvEZuI2URdnknsBvCiwdK2pw6LAwh2ULY1QDHw3TcGO7UoeIuVl3du-Q72os-T-Pv09Nsr2KcYvdSsndfQ2_wq1RsTe22St_Uq-wsl4i2a
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Influence+of+Mechanical+Ventilation+on+the+Pharmacokinetics+of+Vancomycin+Administered+by+Continuous+Infusion+in+Critically+Ill+Patients&rft.jtitle=Antimicrobial+agents+and+chemotherapy&rft.au=Medell%C3%ADn-Garibay%2C+Susanna+Edith&rft.au=Romano-Moreno%2C+Silvia&rft.au=Tejedor-Prado%2C+Pilar&rft.au=Rubio-%C3%81lvaro%2C+Noelia&rft.date=2017-12-01&rft.eissn=1098-6596&rft.volume=61&rft.issue=12&rft_id=info:doi/10.1128%2FAAC.01249-17&rft_id=info%3Apmid%2F28893792&rft.externalDocID=28893792
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0066-4804&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0066-4804&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0066-4804&client=summon